1 / 19

Can Ethics Save Pharma?

Can Ethics Save Pharma?. Arthur L. Caplan Chair Department of Medical Ethics University of Pennsylvania School of Medicine. Demonization of Pharma. Spate of Recent Books and Exposes Angell Kassirer Avorn. Why Demonization?. Ludicrous campaign against Canadian imports

ray
Download Presentation

Can Ethics Save Pharma?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Can Ethics Save Pharma? Arthur L. Caplan Chair Department of Medical Ethics University of Pennsylvania School of Medicine

  2. Demonization of Pharma • Spate of Recent Books and Exposes • Angell • Kassirer • Avorn

  3. Why Demonization? • Ludicrous campaign against Canadian imports • Ridiculous ad campaigns • Prices skyrocketing

  4. Ethical scandals in 2004-2005 • SSRIs and Suicide in children, Glaxo, Lilly • Warner Lambert/Pfizer off label promotion of Neurontin (430 million fine) • SEC Boston --selective disclosure of data • Merck and Vioxx, Pfizer Celebrex • Rapid approval and withdrawal of Tysabri by An Biogen • Amgen GDNF withdrawal/Parkinsonism • NIH and consulting fees • FDA, David Graham and censorship

  5. Demonized • 13% of Americans think pharmaceutically companies are “generally honest and trustworthy” (Harris Poll, 2004) • Public confidence has plunged faster for pharma then any other industry in recent years including managed care, tobacco and oil

  6. But--Pharma is not Tobacco • Pharmaceutical Industry provides invaluable medicines that relieve pain, save lives, and cure patients • Thousands of dedicated and talented employees • Prospects for targeted medicines and genomic and proteomically driven breakthroughs are strong • Key sector in American economy

  7. Exorcizing Demons • Pharma could undertake a huge PR campaign • Pharma could redouble lobbying effortsOR • Pharma could commit to scientific foundation for the industry • Pharma could recommit to ethical guidance for how it does its research, marketing, sales • Pharma could simply stop its worst practices-- • DTC, freebies and handouts

  8. Adverse Events Present Opportunities • Time for Leadership • Time to reduce liability • Time to make health care safer • Time to live up to self-proclaimed ethics of the industry (ethical pharmaceuticals)

  9. DSMBs, CROs and IRBs • Sending a clear message about what is expected • Making sure that composition of these groups reflects public interest and public good • Follow up and study of performance

  10. Creating Registries • The social contract with every subject in medical research • Promise to learn and to advance research • If data is not public it is a betrayal of a promise • The duty to disseminate knowledge • The means to disseminate knowledge

  11. Dealing with bad news • Aggressively pursuing information • Epidemiology must trump marketing • Legal liability is minimized by watching for signs of trouble • When in doubt convene the experts • Call for FDA to toughen phase four monitoring

  12. Registries • Need standardization • Compulsory participation • Auditing • Updating

  13. Selling drugs • The end of blockbusters? • The era of targeted or personalized medicines

  14. The end of Efficacy Efficacy versus Effectiveness • Large randomized controlled trials--are they sufficient? • What about testing in the real world? • Comparator trials

  15. The end of Efficacy Taking Genomics seriously Targeted medicines variable responses in ethnic groups Iressa and Asians, women, etc. How much risk should a patient be allowed to take? Vioxx??? Comparator Trials long, long overdue

  16. Current Frenzy is Masking Emerging Ethical Challenges • Aims of medicine--cure vs. quality • Strategy for selling drugs • The end of efficacy • Rethinking marketing • Accountability • Availability of information • Dealing with the poor and the elderly

  17. Marketing in Crisis • DTC • An admitted failure and a source of shame for the industry • Why not a truce on DTC and strong voluntary guidelines? • Detailing an admitted waste of resources but no one wants to disarm first or unilaterally!

  18. Demands of the Poor: here and abroad • The ethics of doing research in poor nations • Informed consent? • Oversight of research • Whose rules, whose values? • Meeting demands and needs--research targets--what are priorities? • What about the poor?

  19. What needs to be done • Defend quality of life • End unethical marketing • Make all data available in standard format • Reform oversight system • Insure compensation for all injured subjects • Shift to effectiveness not efficacy • Take needs of the poor seriously

More Related